Glossary
Antirheumatic
This word turns up in your notes and inside the name of half the drugs described on this site. It's a category rather than a thing, and the drugs it gathers have almost nothing in common beyond the reason they were prescribed. That's worth knowing, because it changes which question is worth asking.
What the research found.
One review pooled 88 randomized trials covering 31566 people with rheumatoid arthritis. Every targeted tablet and every biologic in it beat placebo on response, with odds ratios running from 3.05 to 5.61. Disease scores improved by between 0.80 and 1.91 points, and disability improved by between 0.21 and 0.34.
That review also tested whether raising the dose of a targeted tablet above the lower recommended level gave any extra benefit, and it didn't. That held on response, on disease score, and on disability alike. Three drugs ranked relatively well across all three of those outcomes, and they were tocilizumab, certolizumab pegol, and upadacitinib.
One study compared 921 pregnancies in women with psoriatic arthritis against 9210 matched pregnancies in women without the condition. Preterm birth was more likely, at an adjusted odds ratio of 1.69 from 1.27 to 2.24, and planned caesarean was more likely at 1.77 from 1.43 to 2.20. Emergency caesarean came in at 1.42, from 1.10 to 1.84.
One review pooled 21 trials and 8361 people with early rheumatoid arthritis. Adalimumab with methotrexate led on remission, at an odds ratio of 2.90 from 1.94 to 4.33, and tocilizumab with methotrexate led on the strictest response measure at 4.41 from 2.29 to 8.49. Only one combination showed a safety signal, and that was tocilizumab with methotrexate at 5.11 from 2.03 to 12.86.
What the word means
Antirheumatic means any drug used to treat a rheumatic disease, and that's the whole definition. It describes a job rather than a kind of drug, which is an unusual thing for a medical word to do, and it's the reason the word turns up in your notes so often without telling you much. A shelf label is close to what it is, since the shelf holds several families of drug that resemble each other in nothing except what they get prescribed for.
You'll meet the word inside longer names, and disease-modifying antirheumatic drug is much the commonest of those, usually shortened to DMARD. Those first two extra words hold nearly all of the meaning. Strip them away and what's left describes the shelf rather than anything standing on it.
What it covers
Three families sit under the word, and they work in ways that don't resemble each other at all. The oldest are tablets that damp the immune system down broadly rather than aiming at anything in particular, and methotrexate is the one most people meet. They've been in use for decades, so the habits around them are settled.
The second family is the newer targeted tablets, which block one signal inside a cell instead of quieting the whole system. They're swallowed like the older ones, and they work nothing like them. The third family is biologics, which are proteins grown in living cells that block one signal outside the cell, injected under the skin or given by a drip because a protein that size wouldn't survive your stomach.
So one word covers a broad damper, a targeted tablet, and an injected protein. What those three share is the reason a doctor reaches for them. Nothing else about them lines up, which is why the category is a poor guide to anything you'd want to know.
Do they work
Against placebo, yes, and one review settles that across the whole category at once. It's the largest piece of evidence on this site, pooling 88 randomized trials and 31566 people with rheumatoid arthritis. Every targeted tablet in it beat placebo, every biologic did too, and that held across three separate outcomes rather than just one.
On response, the odds ratios ran from 3.05 to 5.61. On disease score, the improvements ran from 0.80 to 1.91 points, and on disability they ran from 0.21 to 0.34 of a point. Look at the width of those ranges, because everything beat placebo and the drugs didn't beat it equally. That contrast is the point of this page, and it sits in a single set of figures that a category word would have hidden completely.
Is one of them best
That review ranked the drugs against each other, and the answer that came out isn't a single name. Three came out near the top, ranking relatively well across all three of those outcomes, and those three were tocilizumab, certolizumab pegol, and upadacitinib. Tocilizumab beat the other active drugs on disease score by between 0.49 and 1.11 points.
That's a ranking drawn out of pooled trials rather than a recommendation meant for you. Which drug suits somebody depends on their other illnesses, on how their liver and kidneys are doing, and on what their insurance will cover. A ranking sees none of that, which is why the person holding your chart outranks the table every time.
The dose finding
One result from that review is worth keeping, because it runs against what most people expect. The review tested what happens when the dose of a targeted tablet goes above the lower recommended level, and the answer was that nothing extra happens. That held on response, on disease score, and on disability alike.
This page prints no dose for any drug, and your dose isn't a decision you'd be making alone in any case. The finding is useful for something else entirely, which is understanding a conversation you might otherwise find baffling. It explains why a team may decline to increase a drug that seems not to be working, and why that isn't them giving up on you.
More isn't always the answer here, and there's pooled evidence behind that rather than clinical habit alone. Knowing it before you ask for an increase changes the shape of the conversation. You can ask what else is on the table instead, which is a better question than asking for more of what you already have.
Where the word stops helping
The risks and the choices live at the level of the drug rather than at the level of the category, and one review makes that concrete. It pooled 21 trials and 8361 people with early rheumatoid arthritis. Adalimumab with methotrexate led on remission, at an odds ratio of 2.90 from 1.94 to 4.33, and tocilizumab with methotrexate led on the strictest response measure, at 4.41 from 2.29 to 8.49.
That review found just one safety signal across everything it studied. Tocilizumab with methotrexate showed more side effects, at an odds ratio of 5.11 from 2.03 to 12.86, and nothing of the sort turned up for any of the others. One signal, one combination, and dozens of drugs under the word.
So a sentence about antirheumatic drugs and side effects would be close to meaningless as written. The signal belonged to one combination and the word covers dozens of drugs, so a sentence pitched at the category would be both true and useless. Read the drug rather than the category, because that's where every answer you want is kept.
Pregnancy
One study looked at pregnancy outcomes in women taking these drugs, and both what it covered and what it left out are worth knowing. It compared 921 pregnancies in women with psoriatic arthritis against 9210 matched pregnancies in women without it. The women with the condition differed at the start, being more often obese, more often smokers, and more often living with high blood pressure or diabetes.
Two of the outcomes came out raised, and both are worth reading with the study's limits in mind. Preterm birth came in at an adjusted odds ratio of 1.69, from 1.27 to 2.24, and caesarean delivery at 1.77, from 1.43 to 2.20, for a planned one. An emergency caesarean came in at 1.42, from 1.10 to 1.84. That study also found the risks differed by whether treatment was given, by when it was given, and by which treatment it was.
This page can't take that any further and it shouldn't try. Pregnancy decisions about these drugs belong with your own team, and ideally before conception if there's any choice about the timing. One more thing about that study is worth noting, which is that it covered psoriatic arthritis only, so a different diagnosis means those numbers describe somebody else.
What to take from this
The word says very little on its own, and knowing that is the useful part, because it changes which question you ask. If your notes say antirheumatic, the useful part is the drug name sitting next to it. That name is where everything specific about your treatment has been kept.
The name tells you which family the drug belongs to, how it's taken, what gets monitored while you take it, and what the trials found for that drug in particular. All four of those questions have real answers waiting somewhere in your notes. The category has none, which is the difference between a shelf and what's standing on it.
So the question worth asking isn't what an antirheumatic drug does. It's what this particular one does, for this diagnosis, at this point in the illness. That question has an answer, and the person holding your chart is the one who can give it to you.
Common misconceptions.
Myth. Antirheumatic is the name of a kind of drug.
Reality. It's the name of a job rather than the name of a kind, which is why three quite different things sit underneath it. There are old tablets that damp the whole immune system, newer tablets that block one signal inside a cell, and injected proteins that block one signal outside it. What those three share is the reason they get prescribed.
Myth. If two drugs are both antirheumatic they're interchangeable.
Reality. They aren't, and the review that put them all above placebo also spread them out. Across 88 trials and 31566 people, the odds ratios for response ran from 3.05 all the way to 5.61. Tocilizumab, certolizumab pegol, and upadacitinib ranked relatively well across three outcomes, and tocilizumab beat the other active drugs on disease score by between 0.49 and 1.11 points.
Myth. A higher dose of these drugs works better.
Reality. Not for one family of them, on the evidence in that review. Raising a targeted tablet above the lower recommended level gave no extra benefit on response, none on disease score, and none on disability. That's a finding about those particular drugs rather than a rule about medicine, and your own dose stays a decision for your team.
Myth. The word tells me something about side effects.
Reality. It doesn't, because the risks belong to the drug rather than to the category. One review pooled 21 trials and 8361 people and found a single safety signal across everything it studied, and that signal belonged to one particular combination. It says nothing at all about the other drugs the same word covers.
Myth. Antirheumatic drugs are all taken as tablets.
Reality. Some are and some aren't, and the split follows what the drug is made of. The older ones are tablets and so are the newer targeted ones, but biologics are proteins grown in living cells rather than chemicals built in a factory. They're injected under the skin or given by a drip, because a protein that size wouldn't survive being swallowed.
Related terms.
- DMARDs, the narrower category where most of the meaning lives.
- Biologics, the injected family the word also covers.
- Biologics compared with DMARDs, for the head-to-head evidence.
Questions patients ask.
What does antirheumatic mean?
Any drug used to treat a rheumatic disease, and that really is the whole of it. The word describes the job rather than the drug, which is why it turns up inside longer names like disease-modifying antirheumatic drug. On its own it tells you what a drug is for. It tells you almost nothing about how that drug works, what it asks of you, or what gets watched while you take it.
Which drugs does it cover?
Three families that work in genuinely different ways. The oldest are broad tablets that damp the immune system down rather than aiming anywhere in particular, with methotrexate the one most people meet. The newer targeted tablets are swallowed like the older ones and block a single signal inside a cell. Biologics are proteins grown in living cells, they block one signal outside the cell, and they're injected or given by a drip.
Do they all work?
Against placebo, yes, and the evidence for that is unusually large. One review pooled 88 randomized trials and 31566 people, and every targeted tablet and every biologic in it beat placebo on response, with odds ratios from 3.05 to 5.61. Disease scores improved by between 0.80 and 1.91 points, and disability improved by between 0.21 and 0.34. The width of those ranges is the part worth noticing, because everything beat placebo and nothing beat it equally.
Is one of them best?
That review ranked them, and the answer isn't a single drug. Three ranked relatively well across all three outcomes, and those were tocilizumab, certolizumab pegol, and upadacitinib. Tocilizumab beat the other active drugs on disease score, by between 0.49 and 1.11 points. That's a ranking out of pooled trials rather than a recommendation for any one person, because a ranking can't see your other illnesses or your organs.
Would a higher dose work better?
Not for the targeted tablets, on this evidence. That review tested raising the dose above the lower recommended level, and it gave no extra benefit on response, none on disease score, and none on disability. This page prints no dose figure for any drug, and your own dose is a decision for your team rather than one to make alone. What the finding is good for is knowing that more isn't automatically better here.
What does disease-modifying add?
It narrows the category down to something useful. A disease-modifying antirheumatic drug is one meant to slow the illness itself rather than ease the pain of today, and a painkiller is antirheumatic in the loose sense while being nothing of the kind. Those two extra words hold the meaning, which is why people say DMARD and almost never say antirheumatic on its own.
Does taking one affect pregnancy?
One study looked at that in psoriatic arthritis, comparing 921 pregnancies against 9210 matched ones. Preterm birth was more likely, at an adjusted odds ratio of 1.69 from 1.27 to 2.24, and planned caesarean was more likely at 1.77 from 1.43 to 2.20. The risks differed by whether treatment was given, by when it was given, and by which treatment it was. That's a question for your own team, ideally before conception if there's any choice about timing.
Why does the word appear so much?
Because it's the umbrella every drug family on this site sits under, and the families keep growing. Your notes and your prescriptions will use it. The thing worth taking from this page is that the word says very little by itself, and the drug name after it is where the meaning lives.
References.
- Weng C; Xue L; Wang Q et al. Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis. Ther Adv Musculoskelet Dis. 2021;13:1759720X21999564. 10.1177/1759720X21999564Systematic review and network meta-analysis of randomised controlled trials to April 2020 comparing three JAK inhibitors and eight biologic disease-modifying drugs against placebo or conventional synthetic drugs
- Remaeus K; Johansson K; Granath F et al. Pregnancy Outcomes in Women With Psoriatic Arthritis in Relation to Presence and Timing of Antirheumatic Treatment. Arthritis Rheumatol. 2022;74:486-495. 10.1002/art.41985Swedish nationwide registry-based cohort study of 921 pregnancies in women with psoriatic arthritis and 9210 pregnancies without
- Xu H; Li C; Ding R et al. Efficacy and safety of non-conventional synthetic disease-modifying antirheumatic drugs in early active rheumatoid arthritis: a network meta-analysis. BMC Rheumatol. 2025;10:5. 10.1186/s41927-025-00603-xSystematic review and network meta-analysis of randomised controlled trials to February 2025
- Choy E; Freemantle N; Proudfoot C et al. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses. RMD Open. 2019;5:e000798. 10.1136/rmdopen-2018-000798Systematic literature review and network meta-analyses of 24-week efficacy and safety outcomes
- Decarriere G; Barnetche T; Combe B et al. Most Appropriate Conventional Disease-Modifying Antirheumatic Drug to Combine With Different Advanced Therapies in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis. Arthritis Care Res (Hoboken). 2021;73:873-884. 10.1002/acr.24195Systematic literature review with meta-analysis comparing methotrexate against other conventional synthetic disease-modifying drugs when combined with advanced therapies in rheumatoid arthritis
This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.